New updates have been reported about Alpha Fusion Inc (PC:ALPHA)
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alpha Fusion Inc., headquartered in Tokyo and led by CEO Sunao Fujioka, has initiated a Phase I clinical trial for its novel radiopharmaceutical, af-001, targeting differentiated thyroid cancer. This trial, registered as jRCT2031250472, aims to evaluate the safety and efficacy of af-001, which uses the alpha-emitting isotope astatine-211 ([211At]NaAt) as its active ingredient. The trial is structured into two parts: Part Ia will determine the maximum tolerated dose in patients who are refractory or intolerant to standard therapies, while Part Ib will assess the recommended dose for Phase II trials in patients who have not previously received radioactive iodine (RAI) therapy.
The trial’s development follows promising results from an investigator-initiated study at The University of Osaka, which demonstrated the safety and potential efficacy of af-001 in reducing tumor markers. Conducted at the National Cancer Center Hospital East and other sites in Japan, the study aims to address the limitations of current RAI therapy, which often requires hospitalization due to radiation protection measures. By offering an outpatient treatment option, af-001 could significantly reduce the psychological and financial burdens on patients and healthcare facilities. CEO Sunao Fujioka emphasized Alpha Fusion’s commitment to advancing af-001’s clinical development and exploring further applications of At-211 in cancer treatment. The company is poised to contribute to the field of precision radiopharmaceutical medicine through its innovative approach.